Loratadine as an Anti-inflammatory Agent Against Clostridium difficile Toxin B
Abstract Background Clostridium difficile infection (CDI) is a debilitating nosocomial infection. C. difficile produces toxins A and B, which cause inflammation. Existing therapies have issues with recurrence, cost, and safety. We aim to discover a safe, effective, and economical nonmicrobiological...
Gespeichert in:
Veröffentlicht in: | The Journal of infectious diseases 2024-09, Vol.230 (3), p.545-557 |
---|---|
Hauptverfasser: | , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Abstract
Background
Clostridium difficile infection (CDI) is a debilitating nosocomial infection. C. difficile produces toxins A and B, which cause inflammation. Existing therapies have issues with recurrence, cost, and safety. We aim to discover a safe, effective, and economical nonmicrobiological therapeutic approach against CDI.
Methods
We included human primary peripheral blood mononuclear cells (PBMCs), fresh human colonic explants, and humanized HuCD34-NCG mice. Toxin A+B+ VPI 10463 and A−B+ ribotype 017 C. difficile strains were used. We used single-cell RNA profiling and high-throughput screening to find actionable toxin B–dependent pathways in PBMCs.
Results
Histamine 1 receptor–related drugs were found among the hit compounds that reversed toxin-mediated macrophage inflammatory protein (MIP) 1α expression in PBMCs. We identified loratadine as the safest representative antihistamine for therapeutic development. Loratadine inhibited toxin B–induced MIP-1α secretion in fresh human colonic tissues. Oral loratadine (10 mg/kg/d) maintained survival, inhibited intestinal CCl3 messenger RNA expression, and prevented vancomycin-associated recurrence in the VPI 10463–infected mice and ribotype 017-infected hamsters. Splenocytes from loratadine-treated mice conferred anti-inflammatory effects to the VPI 10463–infected T/B-cell–deficient Rag−/− mice. Oral loratadine suppressed human MIP-1α expression in monocytes/macrophages in toxin B–expressing ribotype 017-infected humanized HuCD34-NCG mice.
Conclusions
Loratadine may be repurposed to optimize existing therapies against CDI.
Lay Summary
Loratadine, a Food and Drug Administration–approved antihistamine, inhibits toxin B–mediated proinflammatory macrophage inflammatory protein 1α secretion from immune cells. Its anti-inflammatory effect ameliorates intestinal inflammation in Clostridium difficile–infected animals. Loratadine may be repurposed to optimize existing therapies.
Graphical Abstract
Graphical Abstract |
---|---|
ISSN: | 0022-1899 1537-6613 1537-6613 |
DOI: | 10.1093/infdis/jiae021 |